Target type: molecularfunction
Binding to adrenomedullin (AM). [GOC:bhm, PMID:10882736]
Adrenomedullin (ADM) is a potent vasodilator peptide that exerts its effects through binding to a G protein-coupled receptor complex composed of the calcitonin receptor-like receptor (CLR) and the receptor activity-modifying protein 2 (RAMP2). Upon ADM binding, the CLR-RAMP2 complex activates intracellular signaling pathways, primarily involving the Gαs protein, leading to an increase in cAMP levels. This cAMP elevation ultimately results in the activation of protein kinase A (PKA), which phosphorylates various downstream targets. The activation of these pathways contributes to the vasodilatory effects of ADM by promoting relaxation of smooth muscle cells, increasing vascular permeability, and inhibiting the release of vasoconstrictors. Furthermore, ADM binding has been shown to stimulate the release of nitric oxide (NO) from endothelial cells, further enhancing vasodilation. The molecular function of ADM binding is therefore characterized by a complex interplay of receptor activation, signaling pathway modulation, and downstream effector activation, ultimately leading to the regulation of vascular tone and other physiological processes.'
"
Protein | Definition | Taxonomy |
---|---|---|
Calcitonin gene-related peptide type 1 receptor | A calcitonin gene-related peptide type 1 receptor that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q16602] | Homo sapiens (human) |
Receptor activity-modifying protein 2 | A receptor activity-modifying protein 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O60895] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
haloperidol | haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety. Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) | aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol | antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist |
azaperone | azaperone : An N-arylpiperazine that is 2-(piperazin-1-yl)pyridine in which the amino hydrogen is replaced by a 3-(4-fluobenzoyl)propyl group. Used mainly as a tranquiliser for pigs and elephants. Azaperone: A butyrophenone used in the treatment of PSYCHOSES. | aminopyridine; aromatic ketone; monofluorobenzenes; N-alkylpiperazine; N-arylpiperazine; tertiary amino compound | antipsychotic agent; dopaminergic antagonist |
telcagepant | telcagepant: structure in first source | ||
mk 3207 | |||
bms 694153 | |||
(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta(b)pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo(4,5-b)pyridin-1-yl)piperidine-1-carboxylate | |||
mk-8825 | |||
atogepant | atogepant : A secondary carboxamide resulting from the formal condensation of the carboxy group of (3'S)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxylic acid with the amino group of (3S,5S,6R)-3-amino-6-methyl-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-2-one. It is a selective oral, small-molecule antagonist of calcitonin gene-related peptide (CGRP) receptor that has been approved for the treatment of migraine. | azaspiro compound; organic heterotetracyclic compound; piperidones; secondary carboxamide; trifluorobenzene | calcitonin gene-related peptide receptor antagonist |